Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Becton Dickinson

Evaluate

January 23, 2023

A year to forget for medtech stocks

The biggest surprise is that there were a handful of risers despite the widespread market turmoil.

Thumbnail
November 18, 2022

Big medtechs’ efficiency starts to recover from Covid

Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.

Article image
Vantage logo
August 31, 2022

Olympus continues medtech’s divestmania

Article image
Vantage logo
July 27, 2022

3M to unstick its healthcare unit

Article image
Vantage logo
July 04, 2022

Medtech research spending set to slow in 2022

And some diagnostics groups are forecast to actually cut R&D outlay this year as the pandemic eases.

Article image
Vantage logo
June 20, 2022

Up-and-down test sales and a bigger Medtronic: medtech in 2028

Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.

Article image
Vantage logo
May 23, 2022

Diagnostics beat implants in the race to market

Roche had the most innovative approvals over the last five years – but took second place in terms of speed.

Article image
Vantage logo
April 05, 2022

Embecta seeks high growth with low tech

The diabetes-focused Becton Dickinson spinoff intends to spend – but can it compete in insulin pumps?

Article image
Vantage logo
March 02, 2022

Zimvie gets a less than rapturous reception

Article image
Vantage logo
February 14, 2022

Covid test revenues to crash in 2022

Article image
Vantage logo
December 16, 2021

Medtronic nosedives on diabetes delays

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up